Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
American Journal of Medical Genetics|August 22, 1997
Are Melnick-Needles syndrome and oto-palato-digital syndrome type II allelic? Observations in a four-generation kindredS Robertson, T Gunn, B Allen, et al.
Pigment Cell Research|October 21, 2000
Biochemical and genetic studies of pigment-type switchingG Barsh, T Gunn, L He, et al.
American Journal of Human Genetics|June 9, 2001
Linkage of otopalatodigital syndrome type 2 (OPD2) to distal Xq28: evidence for allelism with OPD1S P Robertson, S Walsh, M Oldridge, et al.
The Journal of Pediatrics|October 1, 1976
Juvenile diabetes mellitus, optic atrophy, sensory nerve deafness, and diabetes insipidus--a syndromeT Gunn, R Bortolussi, J M Little, et al.
Radiography (London, England : 1995)|May 14, 2026
Measuring AI preparedness in health professions education: Evidence from a national survey of medical radiation science students and new graduatesC Edwards, A Murphy, T Gunn, et al.
Gastro Hep Advances|June 15, 2026
Assessment of Esophageal and Gastric Varices in Patients With Cirrhosis for Clinical Trials: A Centralized Blinded Evaluation SystemNaim Alkhouri, Raj Vuppalanchi, Mazen Noureddin, et al.
Radiography (London, England : 1995)|July 19, 2021
International audit of simulation use in pre-registration medical radiation science trainingP Bridge, N Shiner, A Bolderston, et al.
The American Journal of Gastroenterology|August 12, 2021
Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver DiseaseStephen A Harrison, Seth J Baum, Nadege T Gunn, et al.
Hepatology (Baltimore, Md.)|May 1, 2026
Efficacy and safety of belapectin for the prevention of esophageal varices in patients with MASH cirrhosis: The randomized, placebo-controlled NAVIGATE trialNaga Chalasani, Raj Vuppalanchi, Mazen Noureddin, et al.
Gastroenterology|August 12, 2020
Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic SteatohepatitisStephen A Harrison, Guy Neff, Cynthia D Guy, et al.
Pageof 4